SCHEMBL3225528

SCHEMBL3225528

CC(C)(C)OC(=O)NC1CCN(c2c[nH]c3cccnc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.50
SKP1 P63208 1/20 0.50
SKP2 Q13309 1/20 0.50
PARP1 P09874 3/20 0.48
AKT1 P31749 2/20 0.44
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
JAK1 P23458 2/20 0.43
JAK2 O60674 1/20 0.43
TYK2 P29597 1/20 0.43
JAK3 P52333 1/20 0.43
PDE10A Q9Y233 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
DRD2 P14416 2/20 0.42
KCNA3 P22001 1/20 0.42
EPHX2 P34913 1/20 0.42
DRD3 P35462 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267839 0.96 CKS1B (0.47) CKS1BSKP1SKP2PARP1AKT1
SCHEMBL3220338 0.95 PIM1 (0.50) CKS1BSKP1SKP2PARP1PIM1
SCHEMBL3217405 0.89 MAP4K4 (0.51) PARP1PIM1PIM3PIM2JAK3
SCHEMBL3213874 0.88 MAP4K4 (0.48) CKS1BSKP1SKP2PARP1PIM1
SCHEMBL3222860 0.85 KCNMA1 (0.41)
SCHEMBL3225298 0.80 AAK1 (0.46) JAK1JAK2JAK3PDE10A
SCHEMBL13456048 0.80 AKT1 (0.37) AKT1PIM1PIM3PIM2JAK3
SCHEMBL3214786 0.80 ROCK2 (0.46)
SCHEMBL3621236 0.79 POLB (0.52) CKS1BSKP1SKP2PARP1AKT1
SCHEMBL17531192 0.79 CKS1B (0.54) CKS1BSKP1SKP2PARP1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010024980-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 WO disclosed
WO-2010024980-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 WO disclosed
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 US disclosed
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 US disclosed
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056491-A1 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR4, HTR3B CKS1B 968/4885SKP1 3310/4885SKP2 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.